The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study

Kojiro Hashimoto, Norio Sugawara, Masamichi Ishioka, Kazuhiko Nakamura, Norio Yasui-Furukori Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Hyperprolactinemia is a frequent consequence of treatment with antipsychotics. Earlier studies ha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b1e91c014750410f8e3504db96c98271
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1e91c014750410f8e3504db96c98271
record_format	dspace
spelling	oai:doaj.org-article:b1e91c014750410f8e3504db96c982712021-12-02T02:49:30ZThe effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study1178-2021https://doaj.org/article/b1e91c014750410f8e3504db96c982712014-08-01T00:00:00Zhttp://www.dovepress.com/the-effects-of-additional-treatment-with-terguride-a-partial-dopamine--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Kojiro Hashimoto, Norio Sugawara, Masamichi Ishioka, Kazuhiko Nakamura, Norio Yasui-Furukori Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Hyperprolactinemia is a frequent consequence of treatment with antipsychotics. Earlier studies have indicated that terguride, which is a partial dopamine agonist, reduces the prolactin levels that are induced by prolactinemia. Thus, we examined the dose effects of adjunctive treatment with terguride on the plasma concentrations of prolactin in patients with elevated prolactin levels resulting from antipsychotic treatment. Terguride was concomitantly administered to 20 schizophrenic patients (10 males and 10 females) receiving paliperidone and risperidone. The dose of terguride was 1.0 mg/day. Sample collections for prolactin were conducted before terguride (baseline) and 2–4 weeks after administration. The samples were obtained after the morning dose of terguride. The average (± standard deviation) plasma prolactin concentration during terguride coadministration was significantly lower than the baseline concentration in females (82.3±37.1 ng/mL versus 56.5±28.5 ng/mL, P<0.01) but not in males (28.8±18.0 ng/mL versus 26.2±13.1 ng/mL, not significant). Additionally, a significant correlation between the ratio of prolactin reduction and the baseline prolactin concentration was identified in males (rs=−0.638, P<0.05) but not in females (rs=−0.152, not significant). Many patients complained of various adverse events following terguride administration, such as insomnia, agitation, and/or the aggravation of hallucinations. This study suggests that additional treatment with terguride decreases the prolactin concentrations in females experiencing high prolactin levels as a result of antipsychotic treatment. However, its utility for schizophrenia may be diminished because of its low tolerability. Keywords: hyperprolactinemia, terguride, adjunctive treatment, schizophreniaHashimoto KSugawara NIshioka MNakamura KYasui-Furukori NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1571-1576 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hashimoto K Sugawara N Ishioka M Nakamura K Yasui-Furukori N The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
description	Kojiro Hashimoto, Norio Sugawara, Masamichi Ishioka, Kazuhiko Nakamura, Norio Yasui-Furukori Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Hyperprolactinemia is a frequent consequence of treatment with antipsychotics. Earlier studies have indicated that terguride, which is a partial dopamine agonist, reduces the prolactin levels that are induced by prolactinemia. Thus, we examined the dose effects of adjunctive treatment with terguride on the plasma concentrations of prolactin in patients with elevated prolactin levels resulting from antipsychotic treatment. Terguride was concomitantly administered to 20 schizophrenic patients (10 males and 10 females) receiving paliperidone and risperidone. The dose of terguride was 1.0 mg/day. Sample collections for prolactin were conducted before terguride (baseline) and 2–4 weeks after administration. The samples were obtained after the morning dose of terguride. The average (± standard deviation) plasma prolactin concentration during terguride coadministration was significantly lower than the baseline concentration in females (82.3±37.1 ng/mL versus 56.5±28.5 ng/mL, P<0.01) but not in males (28.8±18.0 ng/mL versus 26.2±13.1 ng/mL, not significant). Additionally, a significant correlation between the ratio of prolactin reduction and the baseline prolactin concentration was identified in males (rs=−0.638, P<0.05) but not in females (rs=−0.152, not significant). Many patients complained of various adverse events following terguride administration, such as insomnia, agitation, and/or the aggravation of hallucinations. This study suggests that additional treatment with terguride decreases the prolactin concentrations in females experiencing high prolactin levels as a result of antipsychotic treatment. However, its utility for schizophrenia may be diminished because of its low tolerability. Keywords: hyperprolactinemia, terguride, adjunctive treatment, schizophrenia
format	article
author	Hashimoto K Sugawara N Ishioka M Nakamura K Yasui-Furukori N
author_facet	Hashimoto K Sugawara N Ishioka M Nakamura K Yasui-Furukori N
author_sort	Hashimoto K
title	The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
title_short	The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
title_full	The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
title_fullStr	The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
title_full_unstemmed	The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
title_sort	effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/b1e91c014750410f8e3504db96c98271
work_keys_str_mv	AT hashimotok theeffectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT sugawaran theeffectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT ishiokam theeffectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT nakamurak theeffectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT yasuifurukorin theeffectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT hashimotok effectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT sugawaran effectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT ishiokam effectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT nakamurak effectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy AT yasuifurukorin effectsofadditionaltreatmentwithtergurideapartialdopamineagonistonhyperprolactinemiainducedbyantipsychoticsinschizophreniapatientsapreliminarystudy
_version_	1718402120644820992

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study

Ejemplares similares